A detailed history of Capital International LTD transactions in Abb Vie Inc. stock. As of the latest transaction made, Capital International LTD holds 39,236 shares of ABBV stock, worth $7.06 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares
39,236
Previous 38,419 2.13%
Holding current value
$7.06 Million
Previous $6.59 Million 17.59%
% of portfolio
0.35%
Previous 0.32%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$163.84 - $199.33 $133,857 - $162,852
817 Added 2.13%
39,236 $7.75 Million
Q2 2024

Aug 13, 2024

SELL
$154.79 - $180.76 $23,528 - $27,475
-152 Reduced 0.39%
38,419 $6.59 Million
Q1 2024

May 14, 2024

BUY
$159.82 - $182.1 $3.79 Million - $4.32 Million
23,718 Added 159.68%
38,571 $7.02 Million
Q4 2023

Feb 13, 2024

SELL
$137.6 - $154.97 $219,472 - $247,177
-1,595 Reduced 9.7%
14,853 $2.3 Million
Q3 2023

Nov 13, 2023

BUY
$133.59 - $154.65 $375,387 - $434,566
2,810 Added 20.6%
16,448 $2.45 Million
Q1 2023

May 15, 2023

SELL
$144.61 - $166.54 $1.94 Million - $2.24 Million
-13,448 Reduced 49.65%
13,638 $2.17 Million
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $160,854 - $192,906
1,163 Added 4.49%
27,086 $4.38 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $654,676 - $750,870
4,878 Added 23.18%
25,923 $3.48 Million
Q2 2022

Aug 15, 2022

BUY
$137.62 - $174.96 $2.9 Million - $3.68 Million
21,045 New
21,045 $3.22 Million
Q3 2018

Nov 14, 2018

SELL
$88.91 - $98.84 $1.27 Million - $1.41 Million
-14,250 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$89.56 - $98.21 $1.28 Million - $1.4 Million
14,250
14,250 $1.38 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Capital International LTD Portfolio

Follow Capital International LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International LTD , based on Form 13F filings with the SEC.

News

Stay updated on Capital International LTD with notifications on news.